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A B S T R A C T
Background: The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease
(IBD) remains unclear.
Methods: We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and mainte-
nance of remission in IBD until January 2020 in accordance with PROSPERO protocol (#CRD42018115047).
Relative risk (RR) of maintenance of remission, induction of remission, endoscopic disease activity, and
adverse events were combined in a meta-analysis.
Findings:MTXmonotherapy was not superior to placebo for induction of clinical remission in Crohn’s disease
(CD). However, MTX was superior to placebo in maintaining clinical remission of CD. Concomitant therapy
with MTX and the TNF inhibitor infliximab (IFX) was not superior to IFX monotherapy in CD. In ulcerative
colitis (UC), MTX monotherapy was not superior to placebo neither for induction of clinical remission, nor for
maintenance of clinical remission. MTX did not result in superior endoscopic outcomes during induction or
maintenance therapy compared with placebo. Regarding adverse events (AEs), our meta-analysis on CD stud-
ies showed a significantly higher risk of AEs when comparing MTX versus placebo in studies investigating
induction of remission, but not in maintenance of remission. In UC, no such differences in AEs between MTX
or placebo were observed.
Interpretation: Current data support the efficacy of parenteral MTX monotherapy for maintenance of clinical
remission in CD. MTX is not confirmed to be effective for treatment of UC or for induction of remission in CD.
No evidence supports concomitant MTX to improve efficacy of IFX (no other biologics investigated).









Despite the introduction of a wide range of novel therapeutic
agents for the management of inflammatory bowel disease (IBD),
including biologics (e.g., tumor necrosis factor [TNF] inhibitors, cell-
migration inhibitors, and anti-interleukins) [1,2] and small molecules
(e.g., JAK inhibitors), [3] conventional immunomodulators in the
form of thiopurines and methotrexate (MTX), along with glucocorti-
coids, constitute the basic therapeutic armamentarium. European
and American guidelines recommend MTX for active Crohn’s disease
(CD) as adjunctive therapy or as a steroid-sparing agent to maintain
remission [4,5]. MTX is an inexpensive, well-characterized analogue
of folic acid and aminopterin that targets the enzyme thymidylate
synthetase and dihydrofolate reductase [6]. At high doses (i.e., 
500 mg/m2), MTX was originally introduced as a chemotherapeutic
agent in the 1940s. Later, lower doses of MTX was discovered to have
anti-inflammatory properties and consequently was introduced for a
wide range of chronic inflammatory conditions [7].
For decades, MTX has been used in the management of IBD, char-
acteristically as a second-line immunomodulator and steroid-sparing
agent in patients intolerant to thiopurines or in whom thiopurine
treatment has failed [8,9]. However, current recommendations for
the use of MTX in CD build on data from nearly 500 patients included
in randomized, controlled trials (RCTs) compared with considerably
larger cohorts documenting the effects of the thiopurine family of
immunomodulators. In ulcerative colitis (UC), data have been
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inadequate to recommend MTX, which, nevertheless, has been
widely prescribed for patients failing thiopurines equivalently to CD
[10,11]. Recent state-of-the-art RCTs evaluating adequate dosages of
parenterally administered MTX have, however, shed light on the effi-
cacy of MTX monotherapy in the treatment of UC [12,13].
The objectives of this systematic review of RCTs with a preplanned
meta-analysis were to investigate the clinical efficacy of MTX in IBD for
induction of remission as well as maintenance of remission (defined by
the studies and expressed as a percentage of the total number of
patients randomized (i.e. intention-to-treat analysis)), concomitant
treatment with biologics, and its side effects separated for CD and UC,
respectively.
2. Methods
This systematic review and meta-analysis were performed in
accordance with the guidelines from Cochrane and reported follow-
ing the PRISMA guidelines, and the protocol was registered at the
PROSPERO database (Reg. No. CRD42018115047) before initiation of
the literature search (eAppendix 1).
2.1. Inclusion and exclusion criteria
Studies were eligible for the systematic review if they included (at
least) one treatment group in which MTX was administered for IBD
compared with a non-exposed control group or studies where MTXwas
administered as add-on treatment (e.g., MTX was given in intervention
groups in addition to the control treatment). Studies in children and the
non-English-language literature were excluded. Secondary publications
were checked for additional data before exclusion.
2.2. Search strategy and selection criteria
The following bibliographic databases were searched without
restriction on language and publication year: MEDLINE via PubMed,
EMBASE via Ovid, and the Cochrane Central Register of Controlled
Trials (CENTRAL), all from inception until January 1, 2020. Further-
more, the reference lists of the included studies and systematic
reviews from the last five years on MTX therapy for the management
of IBD were scrutinized for any further studies of relevance.
The following search strategy was performed in MEDLINE and
adjusted to the respective databases: (“inflammatory bowel diseases”
[MeSH] OR Crohn* [TIAB] OR ulcerative colitis* [TIAB] OR IBD [TIAB] OR
Inflammatory bowel disease* [TIAB] OR proctocolitis* [TIAB] OR procto-
sigmoiditis* [TIAB] OR rectocolitis* [TIAB] OR rectosigmoiditis* [TIAB]
OR proctitis* [TIAB]) AND (“methotrexate” [MeSH] OR methotrexate*
[TIAB]) AND (randomized controlled trial [Publication Type] OR con-
trolled clinical trial [Publication Type] OR randomized [TIAB] OR placebo
[TIAB] OR drug therapy [Subheading] OR randomly [TIAB] OR trial
[TIAB] OR groups [TIAB]).
2.3. Data management
A customized data-extraction form was developed for each of the
outcomes (eAppendix 2). Extraction of the following data was consid-
ered mandatory: authors of the study, year of publication, design
of trial, intervention characteristics, location of the trial (in the case
of multicenter studies, primary investigator affiliation), number of
patients allocated (to the MTX versus control groups, respectively),
average patient age, average disease activity score and score applied,
endoscopy score and scoring system applied, number of females
within the intention-to-treat population, and duration of the study
(presented in weeks).
2.3.1. Primary outcome
Efficacy of MTX was accessed based on established disease activity
scores used in IBD. For CD, the Crohn’s disease activity index (CDAI)
score [14] (150 or below is defined as remission; response 70
[Response-70] or response 100 [Response-100]) followed by the
Harvey and Bradshaw index (HBI) score [15] (remission 04, mild
57, moderate 816, and severe 17 [response 3 reduction]). For
UC, the Mayo score [16] (maximum of 12 points; remission 2 [with
no item >1], mild 35, moderate 69, and severe 10; response 3)
or partial score (i.e., without endoscopy [maximum of 9 points];
remission 01, mild 24, moderate 56, and severe 79; response
2), followed by the simple clinical colitis activity index (SCCAI) [17]
(maximum of 15 points including extracolonic manifestations
[1 point per manifestation]; remission 3, mild 46, moderate 79,
and severe 10; response 4).
2.3.2. Secondary outcomes
Endoscopic disease activity scores for mucosal healing, defined as
an absolute subscore for endoscopy of no more than 1 for the Mayo
score [16] (UC); or Crohn’s disease endoscopic index of severity
(CDEIS) [18], followed by the simple endoscopic score for Crohn’s dis-
ease (SES-CD) [19] (both CD scores 2).
Discontinuation of MTX treatment because of side effects was
analyzed and presented as the relative risk (RR). A relative risk larger
than 1 indicates a larger risk of withdrawal in the MTX group versus
the control group.
Research in context
Evidence before this study
For long, the role of methotrexate (MTX) to treat flares or to main-
tain remission in ulcerative colitis (UC) has been uncertain as well
as if MTX as concomitant therapy to biologics is associated with
greater benefits than placebo or alternative therapeutic agents.
Therefore, we searched MEDLINE via PubMed, EMBASE via Ovid,
and the Cochrane Central Register of Controlled Trials (CENTRAL),
all from inception until January 1, 2020 for randomized, controlled
trials evaluating the effectiveness of MTX for inflammatory bowel
disease (IBD).
Added value of this study
To our knowledge, this is the first comprehensive meta-analysis
to evaluate the efficacy of MTX in IBD in a single paper. The
meta-analysis of 10 RCTs with 767 participants showed that par-
enteral MTX is efficacious for maintenance of remission in
Crohn’s disease (CD). However, MTX for induction of remission
is not effective for CD, and far more potent treatment options are
available for treatment of disease flares. In UC, MTX should no
longer be considered as a therapeutic option neither for induc-
tion or maintenance of remission. MTX as concomitant medica-
tion with TNF inhibitors has only been tested with infliximab
(IFX) and in CD, and data does not support superiority of MTX-
IFX combination therapy over IFX monotherapy.
Implications of all the available evidence
Based on the latest evidence, the use of parenteral MTX mono-
therapy in the management of patients with IBD should be
carefully considered and restricted to situations where there is
reliable evidence of benefit, that is in CD as alternative mainte-
nance therapy to thiopurines.
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2.4. Study selection and bias assessment
Two members of the study team (OHN and CS) independently
accessed titles and abstracts for study eligibility, performed data
extraction and assessed risk of bias. The full text was obtained if stud-
ies were judged eligible by at least one reviewer. The same two
reviewers independently judged eligibility of the retrieved full-text
studies. Consensus on inclusion was reached by discussion, including
CBJ and GR. Risk of bias in included studies was evaluated using the
Cochrane risk of bias tool assessing whether each of the following
domains were adequate (i.e., low risk of bias), unclear, or inadequate:
sequence generation, concealment of allocation, blinding, incomplete
outcome data addressed, selective outcome reporting.
2.5. Evidence synthesis
A meta-analysis was applied using the restricted maximum likeli-
hood (REML) method as other methods tend to overestimate the pre-
cision of the estimate. Relative risk (RR) and 95% confidence interval
(CI) were estimated on remission, relapse, endoscopic disease activ-
ity, and adverse events (AEs) in the MTX group versus the placebo
(control) group.
The meta-analysis was stratified on oral or parenteral (very low (i.
e.  12.5 mg/week) or low (i.e., 12.5 - 25 mg/week) dosages of MTX
applied, if possible. Heterogeneity was examined as the between-
study variation and calculated as the I-statistic measuring the propor-
tion of variation (i.e., inconsistency) in the combined estimates owing
to between-study variance.
An I2-value of 0% indicates no inconsistency between the results
of individual trials, and an I2-value of 100% indicates maximal incon-
sistency [20]. For outcome measures for which a meta-analysis was
not possible, the results of the individual studies was presented.
2.6. Role of the funding source
This systematic review and meta-analysis was not funded.
3. Results
3.1. Included studies into the systematic review
The literature search identified 6,018 papers, of which 10 RCTs
were included in the quantitative evaluation (Table 1, Fig. 1). Overall
the study quality was high even though the description of the
method, especially the sequence generation and the allocation con-
cealment in the older studies was inadequate, and therefore assessed
as being unclear (eTable 1). Six studies, including 479 participants,
evaluated the effect in CD (two investigated the effect on induction of
remission [21,22], one investigated the effect on maintaining clinical
remission [23], and three investigated both outcomes) [2426]. Fur-
ther, four trials compared the effect of MTX versus placebo
[2123,25], and two examined the effect of concomitant MTX with
the TNF inhibitor infliximab (IFX) versus IFX alone [24,26]. Concern-
ing UC, four studies, including 288 participants, were identified. One
study investigated induction of remission [12], two investigated
maintenance of clinical remission [13,27], and one studied both out-
comes [28].
3.2. Meta-analysis of MTX in Crohn's disease
Our meta-analysis of the RCTs, presented in Fig. 2 and Table 1,
showed no significant effect of MTX monotherapy in the manage-
ment of CD in three RCTs investigating induction of clinical remission
(primary endpoints) [21,22,25] (RR = 1.44; 95% CI 0.712.94;
I2 = 55%). However, when investigating maintenance of clinical
remission a significant effect in two RCTs was found (RR = 1.50; 95%
CI 1.082.07; I2 = 0%) [23,25]. Nevertheless, none of the published
RCTs in CD assessed endoscopic scores as secondary endpoint. No
effect was observed in studies investigating the additional effect of
concomitant MTX with IFX versus IFX alone on either induction of
clinical remission or maintenance of clinical remission or when
assessing mucosal healing by endoscopy [24,26] (Fig. 2). Moreover,
the effect of MTX on induction or maintenance of endoscopic healing
had not been assessed.
3.3. Meta-analysis of MTX in ulcerative colitis
In UC, the meta-analysis of the primary endpoints showed no
significant effect of MTXmonotherapy in data derived from two stud-
ies investigating induction of clinical remission [12,28] (RR = 1.19;
95% CI 0.721.96; I2 = 33%; Fig. 2), and there was no effect in the
three studies investigating maintenance of clinical remission
[13,27,28] (RR = 1.06; 95% CI 0.791.43; I2 = 32%; Fig. 2). Regarding
the secondary endpoints, endoscopic disease activity, MTX for induc-
tion (RR = 1.37; 95% CI 0.772.46) or maintenance (RR = 0.79; 95% CI
0.431.46) of steroid-free endoscopic remission was not superior to
placebo. [12,13] Nevertheless, MTX combination therapy with biolog-
ics has not yet been investigated in UC.
3.4. Meta-analysis on adverse events of MTX in inflammatory bowel
disease
Regarding AEs, our meta-analysis on CD studies showed a signifi-
cantly higher risk of AEs (defined as MTX withdrawal because of AEs)
in three studies investigating induction of remission (RR = 6.40; 95%
CI 1.5227.03; I2 = 0%) [21,22,25], but no statistical differences in two
studies investigating maintenance of clinical remission (RR = 2.95;
95% CI 0.3128.19; I2 = 0%) [23,25] when comparing the risk of AEs in
the MTX group versus placebo (Fig. 3). Further, no differences were
observed in two studies investing the additional effect of concomi-
tant MTX with IFX versus IFX alone [24,26] (Fig. 3). In studies investi-
gating UC, the meta-analysis showed no differences in the risk of AEs
in two studies investigating induction of remission (RR = 0.74; 95% CI
0.242.26; I2 = 30%) [12,28] or in three studies investigating mainte-
nance of remission (RR = 2.91; 95% CI 0.6812.42; I2 = 0%) [13,27,28]
when comparing the MTX group with the control group.
There was no difference in severe adverse events (SAEs, i.e., leading
to hospitalization) between MTX and placebo as shown in eFig. 1. How-
ever, SAEs were only reported in 6 studies (three out of six studies
reported SAEs in CD, and three out of four in UC). Due to the low num-
ber of reported SAEs, no significant results were found in any of the ana-
lyzed subgroups, and the 95% CI were accordingly broad (eFig. 1).
4. Discussion
This is the first systematic review andmeta-analysis of the combined
efficacy of MTX for induction of remission and maintenance of remis-
sion in both CD and UC, respectively, based on the latest RCTs. In the
late 1980s, the first promising pilot studies were published on MTX
monotherapy for IBD indicating a steroid-sparing effect and an ability to
induce and maintain clinical remission or even mucosal healing in
patients with either steroid-refractory or steroid-dependent disease
[29,30]. Over the years, several uncontrolled observational studies
[3140], along with minor RCTs have indicated a benefit of MTX in par-
ticular among patients with CD failing thiopurines, but only three state-
of-the-art RCTs have supported its clinical efficacy in CD [2224].
As concerns dosage used in the 10 RCTs included in the quantita-
tive evaluation, in CD two of the older studies (published before
2000) an oral administration was used [21,25], whereas all studies
(both before and after year of 2000) from Feagan et al. [2224] used
parenteral administration. The dose of MTX ranged from 10 to
25 mg/week with no clear tendency to have changed over time.
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Table 1
Randomized, Controlled Trials Evaluating MTX for CD or UC.
Reference
and year
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In the older studies of UC published before 2000 [27, 28] an oral
administration was used in contrast to the newer ones (after 2010)
[12,13] which used parenteral administration. Here the dose of MTX,
however, changed over time from 12.515 mg/week in older studies
[27,28] to 25 mg/week in the newer ones, including maintenance of
remission [12,13].
This meta-analysis shows that MTX monotherapy is not superior
to placebo for induction of clinical (i.e., symptomatic) remission in CD
when defined as CDAI < 150 (primary outcome). However, the evi-
dence of no effect of MTX for induction of remission may be low due
to heterogeneity and sparse number of studies. Nevertheless, more
efficient agents with better safety profiles are available for this indi-
cation, and most European and American guidelines do not recom-
mend MTX monotherapy to induce remission in CD [4,41], although
a recent Canadian guideline for management of luminal CD made a
conditional recommendation based on very low-quality evidence
that parenteral MTX may be employed in corticosteroid-dependent/
resistant CD to induce remission [42].
For maintenance of clinical remission in patients with CD, how-
ever, this meta-analysis concludes that MTX monotherapy is superior
to placebo. This is also reflected by European and American
guidelines, where MTX is advised as a maintenance agent in CD
[4,41]. Further, parenteral dosages of MTX below 15 mg have not
been shown to be effective for maintenance of clinical remission,
although the minimal dose of MTX required to maintain remission
has not been adequately investigated [41]. Of note, from the meta-
analysis it seems that oral administration of MTX have not proven to
be effective for maintenance of remission in CD.
Whereas the efficacy of MTX monotherapy has been reasonably
well documented in CD, until recently its effectiveness in UC has
been equivocal because of several uncontrolled observational studies
characterized by small sample sizes, suboptimal oral doses of MTX,
poorly designed inclusion criteria, and overall less encouraging find-
ings [10,27,29,30,33,40,4345]. Despite such failings, MTX therapy
has been applied in UC equivalently to CD under the assumption that
MTX inhibits dihydrofolate reductase and thus restricts DNA, RNA,
and protein synthesis, which is equally effective in both diseases
[10,11]. However, because the mechanism of action of MTX dosages
of 25 mg/week is more uncertain than the crude cytotoxic effect
employed for malignancies with substantially higher doses [46], and
because the inflammatory mechanisms differ between UC and CD,
this extrapolation may have been unsubstantiated.
Fig. 1. Study screening and selection flow diagram.
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Until recently, well-established disease activity indices such as the
CDAI [14] (and the Mayo score [16] for UC) have been used as “gold
standards” to evaluate therapeutic efficacies of drugs, including MTX.
Nonetheless, advances in field of endoscopy have expanded our knowl-
edge of the relatively poor agreement between these partially symp-
tom-driven indices and objective endoscopic findings of the degree of
intestinal inflammation. Furthermore, these indices have been shown to
be prone to intra- and interindividual variability [4749]. This has lately
resulted in a paradigm shift in disease monitoring and trial reporting in
IBD because regulatory authorities now require efficacy to be docu-
mented by healing of the intestinal mucosa, which is considered a more
appropriate clinically and prognostically relevant outcome measure
[50,51]. Only limited and low-quality data exist on the ability of MTX
monotherapy to induce and maintain endoscopic healing in CD, and
these data have thus far not been encouraging [30,5254]. Thus recom-
mendations for the use of MTX in CD are based on symptomatic
Fig. 2. Use of MTX for the management of CD and UC in the context of disease activity measured on induction and maintenance of remission (primary outcome). CI, confidence
interval.
6 O.H. Nielsen et al. / EClinicalMedicine 20 (2020) 100271
improvements that have not been backed up by objective endoscopic
documentation of treatment efficacy.
Efficacy of MTX in UC was recently assessed in two landmark RCTs
including endoscopic assessment of mucosal healing: the METEOR
trial [12] and the MERIT-UC trial [13]. Although METEOR provided
uncertain results regarding the efficacy of MTX as an induction ther-
apy for UC (the primary endpoint as well as nine of 10 secondary end-
points failed), it could be argued that MTX may be used to provide a
bridge to another agent for maintenance therapy by reducing the
symptoms of active disease and the need for glucocorticoids. Never-
theless, the results of the MERIT-UC study exclude any role of MTX in
maintaining remission in UC [13]. Of note, MTX monotherapy did not
provide higher rates of endoscopic healing than placebo in UC.
Three underpowered RCTs of which two used an oral dose of MTX,
have compared the efficacy of MTX with that of thiopurines in induc-
ing and maintaining remission in patients with CD. Although these
studies indicated a comparable efficacy and a similar time to onset of
action [25,44,55], thiopurines have generally been preferred over
Fig. 3. Adverse events (AEs) reported when using parenteral MTX for the management of CD and UC. AEs were defined as withdrawal because of AEs. CI, confidence interval.
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MTX in the treatment of CD because of their oral administration and
better levels of efficacy and safety evidenced.
No data exist on the efficacy of MTX in the postoperative prophy-
laxis of CD. Preoperative MTX treatment has not been associated
with an increased risk of postoperative complications [56]. Apart
from case series [26,5759] and a subgroup analysis of a tiny RCT
comparing azathioprine and MTX for induction of fistula closure with
similar remission rates observed [55], no data are available on the
efficacy of MTX in the treatment of fistulizing CD [60].
Because MTX monotherapy is a keystone in the management of
rheumatic disorders, including peripheral arthritis and axial arthrop-
athies [61], it can be tried as a primary immunosuppressive agent in
patients with CD [62] in order to target both joints and gut [63],
although this has not been investigated in RCTs. Likewise, MTX is not
being associated with development of malignancies and may be pre-
ferred over thiopurines in patients with CD and a previous history of
cancer, whereas thiopurines are well-known to increase risks of lym-
phomas and skin cancers [64,65].
As concerns the efficacy of MTX as concomitant therapy with TNF
inhibitors, the COMMIT RCT investigated treatment outcomes of IFX
monotherapy (standard induction of 5 mg/kg at weeks 0, 2, and 6 fol-
lowed bymaintenance therapy of 5mg/kg every 8 weeks; n = 63) versus
MTX-IFX combination therapy (25 mg subcutaneously weekly; n = 63)
for 50 weeks and with prednisone tapering no later than week 14 [24].
The primary outcome was time to treatment failure, defined as failure
to enter prednisone-free remission (CDAI < 150) at week 14 or failure
to maintain this remission through week 50. The actuarial rate of treat-
ment failure was 31% in the combined MTX-IFX therapy group, and 30%
in the IFX monotherapy group, and secondary endpoints were all nega-
tive as well [24]. Thus, at week 52, 56% of patients in combination treat-
ment maintained remission versus 57% in the IFX group [24].
Endoscopic outcomes were not assessed. However, some lower-quality
studies have revealed comparable findings [26,66]. Moreover, a recent
retrospective observational real-world study concluded that concomi-
tant MTX-IFX therapy for at least three months was inferior to IFX-thio-
purine combined therapy [67]. Finally, a retrospective study found that
very low-dose MTX (i.e.  12.5 mg/week) was equally efficient to the
typical anti-inflammatory dose of MTX (12.525 mg/week) in combina-
tion with TNF inhibitors [68].
Although improved efficacy of combination therapy with MTX
and biologics remains to be shown, it appears that MTX to some
extent can suppress antibodies against IFX and/or increase IFX trough
levels in CD [24,6973]. This phenomenon has been mechanistically
related to a possible interaction between MTX and B-cell activating
factor (BAFF) [74]. Initiation of combination therapy with MTX in
addition to continued treatment with an existing TNF inhibitor has
been reported to potentially reverse antidrug antibodypositive sta-
tus, increase blood levels, and reestablish clinical efficacy [7072].
However, if used for this indication, potential side effects to both
MTX and continued IFX therapy in the presence of anti-IFX antibodies
should be balanced against switching to another biologic agent. MTX
combination therapy has so far not been examined for UC or for other
biologics [6,75,76].
The strength of this meta-analysis is the comprehensive search
strategy in relevant databases and that study-selection and risk of
bias evaluation was performed by two reviewers independently.
Moreover, all RCTs on MTX for IBD in adults published up to 2020
were included, and state-of-the-art statistics (i.e. the restricted maxi-
mum likelihood (REML) method) has been applied. However, the
review at the same time has some limitations due to the design of
the underlying RCTs which were eligible for inclusion. First, the inter-
vention period was not consistent among studies (i.e., a variation
from 24 weeks to 1 year was observed). Second, risk of bias from ran-
dom sequence generation, concealment of allocation, blinding,
incomplete outcome addressed, and selective outcome reporting var-
ied among the RCTs included (eTable 1). Third, heterogeneity was
seen among the results of the individual trials, and few studies
reported on disease activity and side effects defined as withdrawal
because of AEs. Fourth, concomitant therapy with IFX was reported
in only two of 10 studies (and in CD only), and in an attempt to
reduce heterogeneity, subgroup analyses were performed with or
without combined therapy for induction of remission or maintenance
of clinical remission among patients with CD, resulting in very few
studies for each meta-analysis. Publications bias (i.e. small study
bias) was not investigated due the small number of studies, however,
visual inspection of the forest plot did not indicate that small study
bias influenced the interpretation of the results.
The sum of available evidence extracted from this meta-analysis
supports the effectiveness of MTX monotherapy (parenterally at
1525 mg/weekly) in maintaining clinical remission of CD, whereas
its role in induction of clinical remission is doubtful. However, any
future studies on CD would benefit from inclusion of mucosal healing
in the scoring systems applied. Moreover, for some special indica-
tions such as extraintestinal rheumatic manifestations of peripheral
arthritis and axial arthropathies or in case of previous malignancies,
MTX may be considered as a useful primary maintenance agent of
CD, although RCTs in the field are still missing. Finally, more evidence
is needed to assess the potential benefit of MTX as a concomitant
agent to improve the clinical efficacy and/or pharmacokinetics of dif-
ferent types of biologic agents in IBD.
In conclusion considering the advent of recent high-quality RCTs
on patients with UC, including both symptomatic and endoscopic
endpoints as recommended by regulatory agencies on both sides of
the Atlantic [77,78], data from this systematic review and meta-anal-
ysis indicate that it is time to critically readdress the use of MTX in
the management of IBD. Thus, when collectively considering this effi-
cacy in adults (i.e., patients of 18 years or older), including lack of
data on mucosal healing, safety, and compliance, it is recommended
that MTX is being reserved primarily as an option for maintaining
clinical remission in CD as an alternative to thiopurines. Even though
it cannot be completely ruled out that MTX may have some limited
benefits over placebo in the symptomatic treatment of flaring UC, the
availability of far more potent and well-documented agents that can
induce mucosal healing, including biologics [79] and novel small-
molecule drugs [2], renders MTX—based on this systematic review
and meta-analysis—not to be confirmed efficient in the treatment of
acute flares of IBD. Furthermore, MTX is not confirmed to be effective
in the maintenance of clinical or endoscopic remission in UC.
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